About Us- copy

Reviva Pharmaceuticals Holdings, Inc., (“Reviva”) headquartered in Cupertino, California, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burden to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory, and metabolic diseases. Reviva is using chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Reviva’s pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.

The leadership and management team is comprised of highly successful and experienced professionals from the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market.

Speed without sacrificing quality is one of the hallmarks of Reviva’s product development model. The company has a strong patent portfolio and promising multiple products in the pipeline at various stages of development. The company’s lead product RP5063 is a multimodal neuromodulator which has successfully completed the global Phase 2 clinical trials and has shown a superior efficacy and safety profile for schizophrenia and schizo affective disorder. After having a very successful End of Phase 2 ( EOP2 ) meeting with U.S. FDA, the company is now preparing to start the global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. The company is also planning to develop RP5063 for bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis/agitation (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD) and autism spectrum.

TOP